Evidence suggests that nevirapine, a non-nucleoside reverse transcriptase i
nhibitor, might be very effective in the prevention of HIV-1 integration an
d the reduction of risk of HIV-1 acquisition after exposure. We used a trip
le combination regimen, including nevirapine, for prophylaxis after occupat
ional or sexual exposure to HIV-1 infection. Of 57 individuals who started
therapy, only 41 returned for follow-up. Five had a grade three or four dru
g-induced hepatitis, two of whom also had a rash. This high rate of major a
dverse events raises concerns over the safety of such a regimen for its use
in this population.